{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:11:56Z","timestamp":1791889916486,"version":"4.3.4"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1016\/j.pharmthera.2008.02.012","type":"journal-article","created":{"date-parts":[[2008,4,30]],"date-time":"2008-04-30T11:38:36Z","timestamp":1209555516000},"page":"1-6","source":"Crossref","is-referenced-by-count":19,"title":["Management of hepatorenal syndrome"],"prefix":"10.1016","volume":"119","author":[{"given":"P.A.","family":"McCormick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2008.02.012_bib1","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1053\/gast.2000.20189","article-title":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial","volume":"119","author":"Akriviadis","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib2","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/00042737-200212000-00013","article-title":"Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2","volume":"14","author":"Alessandria","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib3","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","article-title":"Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide","volume":"29","author":"Angeli","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hep.510230122","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis","volume":"23","author":"Arroyo","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/gut.47.2.288","article-title":"Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome; a phase II study","volume":"47","author":"Brensing","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib6","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/lt.20445","article-title":"Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation","volume":"11","author":"Campbell","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib7","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1053\/jhep.2001.27830","article-title":"Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis","volume":"34","author":"Cardenas","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/01.CIR.38.1.151","article-title":"Systemic vasoconstrictor and renal vasodilator effects of PLV-2 (octapressin) in man","volume":"38","author":"Cohn","year":"1968","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib9","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1046\/j.1440-1746.2002.02816.x","article-title":"Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis","volume":"17","author":"Colle","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2125.2007.02921.x","article-title":"Ischaemic complications of glypressin in liver disease: a case series","volume":"64","author":"Donnellan","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/jhep.2002.34343","article-title":"Effect of noradrenalin and albumin in patients with type 1 hepatorenal syndrome: a pilot study","volume":"36","author":"Duvoux","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0002-9343(70)80073-0","article-title":"Renal failure in the patient with cirrhosis. The role of active vasoconstriction","volume":"49","author":"Epstein","year":"1970","journal-title":"Am J Med"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib13","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s10620-006-9312-0","article-title":"Octreotide\/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome","volume":"52","author":"Esrailian","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib14","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1365-2036.2006.03086.x","article-title":"Meta-analysis: terlipressin therapy for the hepatorenal syndrome","volume":"24","author":"Fabrizi","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/hep.21443","article-title":"Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features","volume":"45","author":"Fasolato","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib16","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1053\/j.gastro.2007.06.065","article-title":"Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis","volume":"133","author":"Fernandez","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hep.20509","article-title":"Benefit of TIPS for patients with refractory or recidivant ascites: serum bilirubin may make the difference","volume":"41","author":"Gerbes","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","article-title":"Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites","volume":"105","author":"Gines","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib19","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(03)14903-3","article-title":"Hepatorenal syndrome","volume":"362","author":"Gines","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pharmthera.2008.02.012_bib20","first-page":"CD005162","article-title":"Terlipressin for hepatorenal syndrome","volume":"18","author":"Gluud","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00007890-199102000-00030","article-title":"Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome\u2014experience in 300 patients","volume":"51","author":"Gonwa","year":"1991","journal-title":"Tranplantation"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.510270107","article-title":"Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion","volume":"27","author":"Guevara","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib23","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/hep.510280219","article-title":"Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems","volume":"28","author":"Guevara","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib24","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/hep.510300430","article-title":"Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine","volume":"30","author":"Gulberg","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00042737-200202000-00009","article-title":"Effect of terlipressin (glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study","volume":"14","author":"Halimi","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib26","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1152\/ajplegacy.1976.231.5.1579","article-title":"Effects of angiotensin, vasopressin, and methoxamine on cardiac function and blood flow distribution in conscious dogs","volume":"231","author":"Heyndrickz","year":"1976","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib27","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1056\/NEJM197311292892201","article-title":"Recovery from \u201chepatorenal syndrome\u201d after orthotopic liver transplantation","volume":"289","author":"Iwatsuki","year":"1973","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib28","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/gut.40.5.664","article-title":"Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man?","volume":"40","author":"Jalan","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib29","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1572-0241.2005.40899.x","article-title":"The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites","volume":"100","author":"Kalambokis","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib30","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1365-2044.2004.03877.x","article-title":"Vasopressin and terlipressin: pharmacology and its clinical relevance","volume":"59","author":"Kam","year":"2004","journal-title":"Anaesthesia"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib31","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/ndt\/gfh930","article-title":"Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study","volume":"20","author":"Kiser","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib32","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJM196906192802501","article-title":"Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease","volume":"280","author":"Koppel","year":"1969","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/bja\/ael177","article-title":"One year outcome of intensive care patients with decompensated alcoholic liver disease","volume":"97","author":"Mackle","year":"2006","journal-title":"Br J Anaesthesia"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib34","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/ndt\/gfi212","article-title":"The course of type 1 hepato-renal syndrome post liver transplantation","volume":"21","author":"Marik","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2036.1994.tb00288.x","article-title":"Review article: the transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of portal hypertension","volume":"8","author":"McCormick","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib36","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.510250408","article-title":"A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients","volume":"25","author":"McCormick","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/lv.2000.6355","article-title":"Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective randomized, controlled clinical trial","volume":"6","author":"Mitzner","year":"2000","journal-title":"Liver Transpl"},{"issue":"Suppl 3","key":"10.1016\/j.pharmthera.2008.02.012_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2036.2004.02112.x","article-title":"Pathogenesis and pathophysiology of hepatorenal syndrome\u2014is there scope for prevention?","volume":"20","author":"Moller","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib39","doi-asserted-by":"crossref","first-page":"G970","DOI":"10.1152\/ajpgi.00521.2002","article-title":"Central and noncentral blood volumes in cirrhosis: relationship to anthropometrics and gender","volume":"284","author":"Moller","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib40","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hep.21094","article-title":"The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond","volume":"43","author":"Moreau","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib41","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/gast.2002.32364","article-title":"Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study","volume":"122","author":"Moreau","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib42","first-page":"15","article-title":"Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study","volume":"64","author":"Mulkay","year":"2001","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/hep.1840060213","article-title":"Sodium excretion in advanced cirrhosis: effects of expansion of central blood volume blood volume and suppression of plasma aldosterone","volume":"6","author":"Nicholls","year":"1986","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib44","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/jhep.2002.35819","article-title":"Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, non-randomized study","volume":"36","author":"Ortega","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib45","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1345\/aph.1K295","article-title":"Risk factors for developing gadolium-induced nephrogenic systemic fibrosis","volume":"41","author":"Peak","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib46","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/jhep.2003.50276","article-title":"Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"38","author":"Pomier-Layrargues","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib47","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2003.09.019","article-title":"Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study","volume":"40","author":"Restuccia","year":"2004","journal-title":"J Hepatology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib48","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/gut.2004.058636","article-title":"Trends in mortality after hospital admission for liver cirrhosis in an English population from 1968 to 1999","volume":"54","author":"Roberts","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib49","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lt.21149","article-title":"Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT)","volume":"13","author":"Ruiz","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib50","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/archsurg.141.8.735","article-title":"Long-term analysis of combined liver and kidney transplantation at a single centre","volume":"141","author":"Ruiz","year":"2006","journal-title":"Arch Surg"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib51","first-page":"1310","article-title":"Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis","volume":"56","author":"Salerno","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib52","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1053\/j.gastro.2007.06.020","article-title":"Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data","volume":"133","author":"Salerno","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib53","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1152\/ajplegacy.1974.227.5.998","article-title":"Regional vascular effects of vasopressin: plasma levels and circulatory responses","volume":"227","author":"Schmid","year":"1974","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib54","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","article-title":"Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis","volume":"8","author":"Schrier","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib55","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial","volume":"18","author":"Solanki","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib56","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0168-8278(87)80569-X","article-title":"Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome","volume":"5","author":"Solis-Herruzo","year":"1987","journal-title":"J Hepatol"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib57","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM199908053410603","article-title":"Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"341","author":"Sort","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib58","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1053\/j.gastro.2005.09.024","article-title":"Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score","volume":"129","author":"Terra","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib59","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00000542-200609000-00026","article-title":"The vasopressin system: physiology and clinical strategies","volume":"105","author":"Treschan","year":"2006","journal-title":"Anesthesia"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(00)80158-0","article-title":"Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome","volume":"33","author":"Uriz","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib61","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.20262","article-title":"Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome","volume":"40","author":"Wong","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2008.02.012_bib62","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/hep.21940","article-title":"Lack of renal improvement with nonselective endothelin antagonism with Tezosentan in Type 2 hepatorenal syndrome","volume":"47","author":"Wong","year":"2008","journal-title":"Hepatology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725808000673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725808000673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T17:45:45Z","timestamp":1557510345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725808000673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S0163725808000673"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2008.02.012","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}